As President and Chief Executive Officer, Board member of Hengrui Therapeutics, Inc.  Dr. Zong is a seasoned pharmaceutical executive, with extensive leadership experiences in areas of corporate strategy, marketing and commercialization, new product development and launch, and licensing and business development.  Prior to establishing Hengrui Therapeutics, Inc. in February 2016, Dr. Zong led the global business development and licensing in oncology at Merck, responsible for search and evaluation activities and successfully executed numerous critical merger & acquisition, licensing and strategic/clinical collaboration and partnership transactions.  From 2010 to 2014, Dr. Zong managed the Hematology Portfolio and Tumor Strategy Group at Bristol-Myers Squibb, where he developed the hematology strategy and led new product development for hematologic malignancies.  From 2003-2008, Dr. Zong headed the Global Oncology Franchise Development Department at Schering-Plough, now part of Merck, responsible for global strategy, new product development, medical affairs and life cycle management for the billion-dollar global oncology franchise.  Before joining Schering-Plough, Dr. Zong was responsible for marketing, licensing and new product development in the therapeutic areas of cardiovascular/metabolic disorders, urology and infectious diseases in the New Product Development Group at Pfizer.  Over his career, Dr. Zong has played instrumental leadership roles in multiple global pharmaceutical companies, led over 50 new clinical programs treating cancer and other severe diseases, delivered 5 new cancer drugs/indications to patients, and orchestrated numerous business development, licensing and merger & acquisition transactions.  Dr. Zong graduated summa cum laude from Fudan University in Shanghai majored in genetic engineering.  He received his PhD degree in oncology/virology from The Rockefeller University.  Dr. Zong also received an MBA degree in finance and entrepreneurial management from The Wharton School.  Dr. Zong holds 6 scientific/clinical patents related to multiple pharmaceutical innovations.